Study of RAS inhibitors for advanced RAS-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your cancer is advanced or has spread and can't be removed with surgery
- You have non-small cell lung cancer with a specific RAS mutation (like KRAS G12C or G12D)
- You have already received at least one standard treatment for your cancer
- You are in good enough health to be up and about (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
This trial tests whether adding a new drug (zoldonrasib) to standard chemotherapy and immunotherapy can help people with a specific type of lung cancer. It is for those with a RAS G12D mutation and no prior treatment for metastatic disease.
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Hear when a new Non-Small Cell Lung Cancer, NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.